{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-001488","form_type":"8-K","ticker":null,"cik":"0001656634","company_name":"Gritstone bio, Inc.","filed_at":"2025-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.334550+00:00","generated_at":"2026-05-28T14:33:54.825260+00:00","sec_items":["1.01","2.01","1.03","5.02","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Gritstone bio sells assets for $21.25M to Seattle Project Corp. in Ch11; CEO and top officers resign","bullets":["Sold substantially all assets (excl. machinery, Binder IP) to Seattle Project Corp. for $21.25M cash at closing.","Effective Dec 31, 2024: CEO Andrew Allen, CBO Matthew Hawryluk, COO Erin Jones, R&D head Karin Jooss resigned without cause.","Celia Economides named interim CEO and CFO effective Dec 31, 2024; no change in compensation.","Bankruptcy Court approved sale on Dec 23, 2024; closing occurred Dec 30, 2024.","Company cautions that trading in common stock (GRTSQ) is highly speculative due to Chapter 11 Case."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-001488","json":"https://secwatch.observer/filing/0001193125-25-001488.json","markdown":"https://secwatch.observer/filing/0001193125-25-001488.md","text":"https://secwatch.observer/filing/0001193125-25-001488.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1656634/000119312525001488/0001193125-25-001488-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1656634/000119312525001488/d905705d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T14:33:54.825260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7e482fe094","claim":"Matthew Hawryluk resigned as Executive Vice President and Chief Business Officer at Gritstone bio, Inc..","evidence_excerpt":"Matthew Hawryluk, Ph.D., Executive Vice President and Chief Business Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1656634/000119312525001488/0001193125-25-001488-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President and Chief Business Officer"}],"fact_type":"executive_change"},{"claim_id":"a501f1d9d2","claim":"Vassiliki \"Celia\" Economides was appointed as interim Chief Executive Officer and Chief Financial Officer at Gritstone bio, Inc..","evidence_excerpt":"Also effective December 31, 2024 and following the closing of the Asset Sale, Vassiliki “Celia” Economides became interim Chief Executive Officer of the Company as well as Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1656634/000119312525001488/0001193125-25-001488-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Executive Officer and Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"c6182809fb","claim":"Karin Jooss resigned as Executive Vice President and Head of Research and Development at Gritstone bio, Inc..","evidence_excerpt":"Karin Jooss, Ph.D., Executive Vice President and Head of Research and Development","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1656634/000119312525001488/0001193125-25-001488-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President and Head of Research and Development"}],"fact_type":"executive_change"},{"claim_id":"d0d204d1e1","claim":"Erin E. Jones resigned as Executive Vice President and Chief Operating Officer at Gritstone bio, Inc..","evidence_excerpt":"Erin E. Jones, Executive Vice President and Chief Operating Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1656634/000119312525001488/0001193125-25-001488-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President and Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"fccbaf672a","claim":"Andrew Allen resigned as President and Chief Executive Officer at Gritstone bio, Inc..","evidence_excerpt":"Andrew Allen, M.D., Ph.D., President and Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1656634/000119312525001488/0001193125-25-001488-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"eed09e244b2168f3b1775ca6fa6b891540ec7a97","claim":"Gritstone bio, Inc. completed a disposition involving Seattle Project Corp. for $21,250,000 in cash (closed 2024-12-30).","evidence_excerpt":"property assets generally known as “Binder IP,” and certain other specifically identified excluded assets) (the “ Company Assets ,” and such sale, the “ Asset Sale ”) for $21,250,000 in cash at the closing of the Asset Sale. On December 30, 2024, the Company and the Bidders closed the Asset Sale contemplated by the APA, thereby completing the disposition of","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1656634/000119312525001488/0001193125-25-001488-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Seattle Project Corp."},{"label":"Consideration","value":"$21,250,000 in cash"},{"label":"Closing","value":"2024-12-30"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}